A Phase 1 Open-Label Multi-Center Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination with Docetaxel in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
Brief description of study
The purpose of this first-in-human (FIH) study is to investigate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and preliminary efficacy of PRT3789 as monotherapy and in combination with Docetaxel in participants with select advanced, recurrent or metastatic solid tumors with a SMARCA4 mutation.
Clinical Study Identifier: s22-01405
ClinicalTrials.gov Identifier: NCT05639751
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
